Lanman Spinal Neurosurgery Opens Up 2-Level prodisc®Cervical SK and Vivo Clinical Trial in Los Angeles

Lanman Spinal Neurosurgery Opens Up 2-Level prodisc®Cervical SK and Vivo Clinical Trial in Los Angeles

Those suffering from advanced neck and arm pain may find themselves to be candidates for a new clinical trial that has opened up recently at the Los Angeles-based practice, Lanman Spinal Neurosurgery, founded by one of the world’s most prominent spinal surgeons, Dr. Todd H. Lanman.

The practice, located in the heart of Beverly Hills, has begun open enrollment for a new patient study featuring two artificial cervical discs designed by spinal device manufacturer, Centinel Spine, including the prodisc C Vivo and prodiscC SK, as compared to the Mobi-C cervical disc, a currently marketed TDR (total disc replacement) device.

Patients experiencing pain in their neck and arms, between the ages of 18 and 69, with no prior surgeries in their cervical spine, who are chosen for the 2-to-1 randomised trial will undergo a surgery in which they will receive a prodiscC Vivo, prodiscC SK, or a Mobi-C. The 2-to-1 randomisation ensures for every two patients getting a prodiscC Vivo or prodiscC SK, one patient will receive a Mobi-C.

The trial compares prodiscC SK and prodiscC Vivo with the approved, currently marketed TDR Mobi-C device as a control to compare safety and effectiveness to treat symptomatic cervical disc disease in subjects who have been unresponsive to non-operative, conservative treatment at two levels.

Disc replacement works by continuing to allow motion between the spinal levels, and with the prodisc devices, motion is provided by a ball and socket design, which allows for physiological range of motion while also ensuring stability to the spine. 

The prodisc cervical discs are low profile, allowing for “stacking” of discs at adjacent spinal levels, otherwise known as multilevel application. The prodiscC Vivo design uses “teeth” fixation to hold the device in place, while the prodiscC SK incorporates low-profile “keels” for fixation. During the clinical trial, Dr. Lanman will choose the appropriate prodisc design to fit the patient’s anatomic needs.  

Dr. Lanman and his Lanman Spinal Neurosurgery team have been at the forefront of spinal medicine and artificial disc replacement for many years, presiding over a majority of the spine world’s clinical trials and studies serving as a principal investigator, such as the Prestige LP and M6-C in recent years, leading to their FDA approvals. 

To be considered as a candidate for the trial, call (310) 385-7755 or email frontdesk@spine.md. Additional information about the clinical trial can be found at www.clinicaltrials.gov(NCT#04012996). 

For more information on Lanman Spinal Neurosurgery, visit www.spine.md.

Categories: NEWS

Write a Comment

Your e-mail address will not be published.
Required fields are marked*